Latest news

Filter by category:

FILTER: ALL CATEGORIESFilter by:

Latest news

19 Jan 2022

Bill & Melinda Gates Foundation and Wellcome pledge $300 million to CEPI to fight COVID-19 and combat threat of future pandemics
New funding commitments will support CEPI’s goal to condense new vaccine development timelines to 100 days, a third of the time it took to develop a COVID-19 vaccine.

Read more

Read article

18 Jan 2022

CEPI and Institut Pasteur de Dakar partner to advance COVID-19 vaccine manufacturing in Africa
In its initial phase, the new modular facility will manufacture up to 300 million doses of COVID-19 vaccine annually for use on the continent.

Read more

21 Dec 2021

Reflections on 2021 from CEPI CEO Dr Richard Hatchett
Dr Richard Hatchett offers his personal reflections on the events of the past year, and looks to the challenges ahead as the world responds to Omicron and prepares for the threat of future pandemics.

Read more

21 Dec 2021

CEPI expands partnership with SK bioscience to develop a ‘variant-proof’ vaccine against SARS-CoV and SARS-CoV-2 variants
CEPI will provide up to $50 million to support the development of a vaccine candidate based on SK’s nanoparticle vaccine platform that could protect against variants of both SARS-CoV, SARS-CoV-2, and other sarbecoviruses.

Read more

17 Dec 2021

CEPI statement: CEO welcomes Emergency Use Listing for NVX-CoV2373
CEPI-supported vaccine is the first protein-based vaccine to receive EUL, a prerequisite for distribution through COVAX.

Read more

13 Dec 2021

CEPI partners with Affinivax to develop a novel COVID-19 vaccine to target variants
New partnership will advance the development of a novel vaccine that could provide broad protection against SARS-CoV-2 variants, and potentially other betacoronaviruses.

Read more

06 Dec 2021

Gritstone bio and CEPI expand vaccine agreement to tackle Omicron variant
CEPI will provide up to $5 million in additional funding to conduct a Phase 1 clinical trial of Gritstone’s Omicron vaccine candidate in South Africa.

Read more

02 Dec 2021

CEPI and MVC co-fund mix-and-match booster trial of COVID-19 vaccines
Clinical trial will evaluate heterologous and fractional booster doses – or ‘mix-and-match’ booster - combinations of MVC-COV1901 with other COVID-19 vaccines.

Read more

Read article

29 Nov 2021

Speech made by CEPI CEO, Dr Richard Hatchett, on the emergence of Omicron variant at today’s World Health Assembly special session
Dr Richard Hatchett, CEO of CEPI, addressed today’s special session of the World Health Assembly—on behalf of the Access to COVID-19 Tools Accelerator.

Read more

26 Nov 2021

CEPI Statement: Emergence of a new SARS-CoV-2 variant, B.1.1.529
Statement from CEPI CEO, Dr Richard Hatchett.

Read more

23 Nov 2021

CEPI funds Aga Khan University-led consortium to conduct mix-and-match trial of COVID-19 vaccines in Pakistan
New collaboration will assess the safety and immunogenicity of heterologous – or ‘mix-and-match’ - combinations of three COVID-19 vaccines currently being deployed in Pakistan.

Read more

©2022 CEPI. All rights reserved